| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/28/2002 | US20020037491 Oral transmucosal delivery |
| 03/28/2002 | US20020037324 Aqueous solubility pharmaceutical formulations |
| 03/28/2002 | US20020037322 Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof |
| 03/28/2002 | US20020037321 Instant water dissolvable encapsulate and process |
| 03/28/2002 | US20020037319 Drug preparations |
| 03/28/2002 | US20020037318 Using copolymer in pharmaceutical and cosmetic preparations |
| 03/28/2002 | US20020037316 Phospholipid-based powders for drug delivery |
| 03/28/2002 | US20020037312 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 03/28/2002 | US20020037311 Transdermal delivery of lasofoxifene |
| 03/28/2002 | US20020037303 Obtaining oil bodies from a cell; washing oil bodies to obtain a washed oil body preparation; formulating washed oil bodies with thioredoxin or thioredoxin reductase into an emulsion |
| 03/28/2002 | US20020037300 Semi-solid delivery vehicle and pharmaceutical compositions |
| 03/28/2002 | US20020037296 For therapy and diagnosis of the human or animal body, anti-tumour prodrugs and those which are specifically activated by the hydroxylation activity of the P- 450 enzyme CYP1B1 |
| 03/28/2002 | US20020037290 Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| 03/28/2002 | US20020037289 Combined methods and compositions for tumor vasculature targeting and tumor treatment |
| 03/28/2002 | US20020037268 Antimicrobial sanitizing lotion with skin protection properties |
| 03/28/2002 | US20020037260 Compositions for treating biofilm |
| 03/28/2002 | US20020037259 Compositions for controlling bacterial colonization |
| 03/28/2002 | US20020037250 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer. |
| 03/28/2002 | US20020036154 Solid pharmaceutical dosage formulation of hydrophobic drugs |
| 03/28/2002 | DE10139115A1 Citalopram enthaltende pharmazeutische Zusammensetzung Citalopram pharmaceutical composition containing |
| 03/28/2002 | DE10045592A1 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie An antibody-TNF TNF inhibitor fusion protein (TNF-Selektokin) as target-specific Prozytokin for tumor therapy |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/28/2002 | DE10042447A1 Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports Protein from the intestines of vertebrates, which absorbs cholesterol, as well as use of this protein for the identification of inhibitors of intestinal cholesterol transport |
| 03/28/2002 | DE10042412A1 Transdermal patch for administering venlafaxin, useful for prophylaxis or therapy of psychoses, especially depression, as well as anxiety, neuroses and psychopathies |
| 03/28/2002 | CA2423703A1 Use of a nucleic acid/pei complex |
| 03/28/2002 | CA2423127A1 Immunogen comprising ligand bound hiv envelope protein |
| 03/28/2002 | CA2422908A1 Dextran-hemoglobin conjugates as blood substitutes |
| 03/28/2002 | CA2422686A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | CA2422524A1 Pei: dna vector formulations for in vitro and in vivo gene delivery |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421798A1 Ultrasonic method and device for wound treatment |
| 03/28/2002 | CA2419434A1 Medicinal composition |
| 03/28/2002 | CA2407465A1 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
| 03/27/2002 | EP1191098A2 Pharmaceutical composition for treatment of duchenne muscular dystrophy |
| 03/27/2002 | EP1190726A2 Liquefied embolic materials capable of sol-gel phase transition and their use |
| 03/27/2002 | EP1190721A2 A method for the anhydrous loading of nicotine onto ion exchange resins |
| 03/27/2002 | EP1190719A1 Colloidal pharmacomodulation of injected pharmaceutical compositions |
| 03/27/2002 | EP1190718A2 Ophthalmic compositions comprising amino alcohols |
| 03/27/2002 | EP1190707A1 High penetration transdermal medicament |
| 03/27/2002 | EP1190706A1 Liposomes |
| 03/27/2002 | EP1190255A1 Epitopes formed by non-covalent association of conjugates |
| 03/27/2002 | EP1190061A1 Streptavidin expressed gene fusions and methods of use thereof |
| 03/27/2002 | EP1189971A2 Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application |
| 03/27/2002 | EP1189947A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 03/27/2002 | EP1189926A2 Rapid dehydration of proteins |
| 03/27/2002 | EP1189857A2 Branched largely insatured fatty alcohols |
| 03/27/2002 | EP1189749A1 Composite laminate and method for its production |
| 03/27/2002 | EP1189690A1 Method for production of microcapsules |
| 03/27/2002 | EP1189641A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/27/2002 | EP1189640A1 Pharmaceutical complex |
| 03/27/2002 | EP1189639A1 Filler binder for tablets |
| 03/27/2002 | EP1189635A1 Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells |
| 03/27/2002 | EP1189634A1 Treating prostate cancer with anti-erbb2 antibodies |
| 03/27/2002 | EP1189625A1 Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| 03/27/2002 | EP1189620A1 Formulation comprising testosteron undecanoate and castor oil |
| 03/27/2002 | EP1189608A1 Levodopa/carbidopa/entacapone pharmaceutical preparation |
| 03/27/2002 | EP1189602A1 Morphine sulphate microgranules, method for preparing same and compositions containing same |
| 03/27/2002 | EP1189600A1 Grf-containing lyophilized pharmaceutical compositions |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189597A1 Oil-core compositions for the sustained release of hydrophobic drugs |
| 03/27/2002 | EP1189596A1 Pharmaceutical composition for nasally administering water-soluble active substances |
| 03/27/2002 | EP1189579A1 Gelled aqueous cosmetic compositions |
| 03/27/2002 | EP1189575A2 Oxidatively stable, long-chain ethyl ester emollients |
| 03/27/2002 | EP0998501B1 Cationic polymers, complexes associating said cationic polymers with therapeutically active substances comprising at least a negative charge, in particular nucleic acids, and their use in gene therapy |
| 03/27/2002 | EP0957931B1 Solid pharmaceutical compositions comprising a cyclosporin and an anionic surfactant |
| 03/27/2002 | EP0869809B1 Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer |
| 03/27/2002 | EP0862915B1 Antibacterial composition for oral administration |
| 03/27/2002 | EP0837673B1 Polymeric lamellar substrate particles for drug delivery |
| 03/27/2002 | EP0828516B1 Skin permeation enhancer compositions using acyl lactylates |
| 03/27/2002 | EP0782448B1 Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions |
| 03/27/2002 | EP0730470B1 Improved interferon polymer conjugates |
| 03/27/2002 | CN1342196A Bifidobacterium in treatment of inflammatory disease |
| 03/27/2002 | CN1342171A Process for production of multiple cross-linked hyaluronic acid derivatives |
| 03/27/2002 | CN1342169A Oxetanone derivatives |
| 03/27/2002 | CN1342099A Chemical method for making pyrithione particle dispersions |
| 03/27/2002 | CN1342087A Preparations stabilized over long time |
| 03/27/2002 | CN1342068A Core tablet for controlled release of gliclazide after oral administration |
| 03/27/2002 | CN1342067A Orally dispersible tablet with low friability and method for preparing same |
| 03/27/2002 | CN1342064A Soy depigmenting and skin care compositions |
| 03/27/2002 | CN1341674A Preparation method of bio-degradable material epsilon-polycaprolactone for medicine |
| 03/27/2002 | CN1341595A Nonviscous protein type synthetic compound or its carrier combined compound |
| 03/27/2002 | CN1341591A Solution of tetrahydrate N-[ortho-(para-trimethyl acetoxyl benzenesulfonamide) benzoyl] glycine monosodium salt and its medicine |
| 03/27/2002 | CN1341451A Beta-cyclodextrin clathrate permeation pump release-controlling preparation |
| 03/27/2002 | CN1341450A Film coating agent insoluble colour material addition method |
| 03/27/2002 | CN1081461C Long-acting oxytracycline composition |
| 03/27/2002 | CN1081459C Transdermal delivery device |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362276 Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| 03/26/2002 | US6362254 Activated water soluble polymer |
| 03/26/2002 | US6362219 Process for the preparation of a formulation of dihydroartemisinin for the control of wide spectrum of malaria |
| 03/26/2002 | US6362167 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
| 03/26/2002 | US6362011 For detection and quantitation of analytes of interest in biochemical and biological substances; for conducting binding assays by measuring luminescence emitted by one or more labeled components of the assay system |
| 03/26/2002 | US6362000 Providing to a mammalian cell a dna sequence encoding viral fusion protein operably linked to promoter active in cell; providing nucleic acid sequence of a retrovirus, nucleic acid sequence encoding gag protein; forming viral vector particles |
| 03/26/2002 | US6361938 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 03/26/2002 | US6361797 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same |
| 03/26/2002 | US6361792 Fluorocarbon emulsion and nonsteroid antiinflammatory agent, antipyretic, nonnarcotic analgesic |
| 03/26/2002 | US6361791 Stable aqueous dispersions including cationic lipids |
| 03/26/2002 | US6361777 Method of coupling polysaccharides to proteins |
| 03/26/2002 | US6361774 Kit comprising, in separate containers: targeting composition selected from antibody or antibody fragment which specifically binds to target site conjugated to enzyme that converts detoxified drug to its cytotoxic form, enzyme, cytotoxic drug |
| 03/26/2002 | US6361768 Hydrophilic ampholytic polymer |